HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy

AIDS

Volumn 13, Issue 6, 1999, Pages

  Deeks, Steven G ^a,b   Hecht, Frederick M ^b   Swanson, Melinda ^c   Elbeik, Tarek ^a   Loftus, Richard ^b   Cohen, P T ^a   Grant, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

CD4; Combination therapy; Observational study; Protease inhibitors; Viral load

Indexed keywords

CD4 ANTIGEN; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA;

ARTICLE; COHORT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; AMBULATORY CARE FACILITIES; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HOSPITALS, UNIVERSITY; HUMANS; RNA, VIRAL; TREATMENT OUTCOME; URBAN POPULATION; VIRAL LOAD;

EID: 0033033234     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199904160-00001     Document Type: Article

References (25)

1. Mouton Y, Alfandari S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-105.
2. Palella F), Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
3. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. N Engt J Med 1997, 337:725-733.
4. Gulick R, Mellors J, Havlir D, et al.: Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100 week follow-up. JAMA 1998, 280:35-41.
5. Saag M, Knowles M, Chang Y, Chapman S, Clendeninn NJ, Viracept Cooperative Study Group: Durable effect of Viracept (nelfinavir mesylate, NFV) in triple combination therapy.
6. Programs and Abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada 1997 [abstract 1-101].
7. Brook RH; Lohr KN: Efficacy, effectiveness, variations, and quality. Boundary-crossing research. Med Care 1985, 23:710-722.
8. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Meet 1996, 334:1011-1017.
9. US Department of Health and Human Services and Henry J. Kaiser Family Foundation: Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR 1998, 47:43-82.
10. Carpenter CC, Fischl M, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 280:78-86.
11. Gazzard B, Moyle G and the BHIVA Guidelines Writing Committee: 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals, lancet 1998, 352:314-316.
12. Fatkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-116.
13. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP: Antiretroviral therapy for adult HIV-infected patients. Recommendations from a State-of-the-Art Conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-infected Patients. JAMA 1993, 270:2583-2589.
14. Carpenter CC, Fischl M, Hammer SM, et aJ.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996, 276:146-154.
15. Carpenter CC, Fischl M, Hammer SM, et al. for the International AIDS Society-USA: Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997, 277:1962-1969.
16. Para MF, Collier A, Coombs R for the ACTG 333 Study Team: ACTG 333: antiviral effects of switching from saquinavir hard capsule (SQVhc) to saquinavir soft gelatin capsule (SQVsgc) vs. switching to indinavir (IDV) after prior saquinavir. Program and Abstracts of the Infectious Diseases Society of America 35th Annual Meeting. San Francisco, 13-16 September, 1997 [abstract 21].
17. Roberts NA, Craig JC, Sheldon J: Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998, 12:453-460.
18. Levy JA: Caution: should we be treating HIV infection early? lancet 1998, 352:982-983.
19. Kaufmann D, Panteleo G, Sudre P, Telenti A: CD4 T cell count in HIV-1 individuals remaining viremic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study [letter]. lancet 1998, 351:723-724.
20. Marschner IC, Collier AC, Coombs RW, et al.: Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40-47.
21. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
22. Lo JC, Mulligan K, Tai VW, et al.: Buffalo hump in men with HIV-1 infection. Lancet 1998, 351:867-870.
23. Miller KD, Jones E, Yanovsk JA, et al.: Visceral abdominal fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
24. Hirsch MS, Conway B, D'Aquila RT, et al., for the International AIDS Society - USA Panel: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998, 279:1984-1991.
25. Havlir DV, Marschner IC, Hirsch MS, et al.: Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engt J Med 1998, 339:1261-1268.